Mainz Biomed NV (NASDAQ:QUCY) Sees Significant Increase in Short Interest

Mainz Biomed NV (NASDAQ:QUCY) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,367,490 shares, a growth of 75.8% from the June 15th total of 1,915,904 shares. Approximately 23.7% of the shares of the company are sold short. Based on an average daily volume of 8,070,542 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on QUCY shares. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a report on Saturday, June 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

Mainz Biomed Price Performance

NASDAQ:QUCY opened at $1.19 on Friday. Mainz Biomed has a 12-month low of $0.30 and a 12-month high of $4.93. The stock’s 50-day simple moving average is $1.96. The stock has a market capitalization of $17.45 million, a PE ratio of -0.02 and a beta of 2.28.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.